At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 1 Feasibility Trial: Improved Staging of Lobular Breast Cancer With Novel Amino Acid Metabolic and Tumor Neovasculature Receptor Imaging
In Brief
A Phase 1 clinical trial evaluating Computed Tomography, Fluciclovine F18, and 2 other interventions for Anatomic Stage IV Breast Cancer AJCC v8 and 3 related conditions. Completed, enrolled 20 participants across 1 site.
Detailed Summary
This phase I trial studies how well fluciclovine positron emission tomography (PET)/computed tomography (CT) and PSMA PET/CT work in helping doctors understand and classify invasive lobular breast cancer in patients with invasive lobular breast cancer that is suspicious for or has spread to other places in the body (metastasized). Fluciclovine and PSMA are radiotracers used in PET/CT imaging scans that emit radiation. The PET/CT scan than picks up the radiation being released to create a picture from within the body. Information learned from this study may help researchers learn how to better identify metastatic disease in invasive lobular breast cancer patients which will impact appropriate staging.
Study Details
Timeline
Interventions
Undergo PET/CT scan
Given IV
Given IV
Undergo PET/CT scan